Available the first time: https://t.co/4UQlqwujiR 2025 On Demand! On Demand gives you access to all lectures, Q & A panels, and STEP talks, and all speaker slides and handouts — all packed with insights you won’t find anywhere else. Non-CME, practical, and finally here.… https://t.co/MHFUWb3az1 https://t.co/cqzZG40Xp5

An Unusual Consult for Myopathy Presentation by Dr. Kelsey Lemmen, at the Rheumatology Winter Clinical Symposia - Feb 2025 https://t.co/DYlzee6qcs https://t.co/nUxTC9roF9

A Review of Relapsing Polychondritis A current review in the Journal of Thoracic Disease on relapsing polychondritis (RP), suggests that while this rare disorder may have an uncertain pathogenesis, its diagnosis and therapeutical management has improved.… https://t.co/keacvqjlU7 https://t.co/TkYwNnYtxF

Crohn’s Microbiome may Predispose to Axial Spondyloarthritis Researchers at Weill Cornell Medicine found that people with Crohn’s disease and related joint inflammation have distinct gut bacteria, with Mediterraneibacter gnavus as a potential biomarker. https://t.co/SI03wAJ3UU https://t.co/dlt3VxBDLw

CDC: More women (25.4%) than men (23.2%) had chronic pain in last 3 mos, Esp in large central metropolitan areas(22% vs 19%, F>M). For both recent chronic pain increased with decreasing urbanicity. https://t.co/rDsCQWvAae https://t.co/mhczpWFsdw

Neuropsychiatric Lupus: More than just a headache Presentation by Dr. Daniel Carlson, at the Rheumatology Winter Clinical Symposia - Feb 2025 https://t.co/v0da4UNFNV https://t.co/BhBKOgak4W

Normalizing Serologies Enhances Remission in SLE Analysis of five phase III belimumab (BEL) trials reveals that normalizing serologies affords protection against severe and renal SLE flares, supporting the concept of treat-to-target to minimize risk in SLE.… https://t.co/eW9EUyvts7 https://t.co/OdM0WkLtjd

Intraarticular Steroids in OA Lowers Need for Pain Meds Is it possible that intra-articular corticosteroid injections for osteoarthritis might affect the use of opioids? https://t.co/pw6vWbFRQx https://t.co/5KrB9uJv7M

Genentech announced that FDA has accepted a Supplemental Biologics License Application for obinutuzumab (anti-CD20 mAb; Gazyva) for the Treatment of Lupus Nephritis based on positive results from Phase III REGENCY study. FDA decision by October 2025 https://t.co/Mx3YDUfkMg https://t.co/MTBZo1TCrK

Sleep disturbance increases disability progression - Prospective cohort data from from 70K Nurses’ Health Study w/ 392 having MS, 7,302 DM, & 25K OA. Having Sleep apnea or disturbances signif incr disability in OA & DM (OR~1.4) as was excessive daytime sleepiness… https://t.co/5PP18gqDqi https://t.co/u1HFOstv8W

FDA grants priority reviews to: - Nicalizumab (J&J; FcRn antibody) for use in Myasthenia gravis. - Upadacitinib (AbbVie; JAK inhib) for use in GCA - Namistat (BI: PDE4B inhib) for use in Idiopathic pulmonary fibrosis - Inalizumab (Hansen; anti-CD19) for use in IG4 rel Dz -… https://t.co/dsg9vZASrk https://t.co/8t2USASmm8

SOCS1 Insufficiency - a Rare Inborn Error of Immunity Lancet Rheumatology has published a population study of the rare suppressor of cytokine signalling 1 (SOCS1) insufficiency - an inborn error of immunity affecting the negative regulation of cytokine and growth factor… https://t.co/I0muoIk5GL https://t.co/jbcuAZivci